Patents
Literature
2 results about "Micafungin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
Echinocandin drug impurity compound, preparation method therefor and use thereof
PCT designated stageWO2026102990A1Peptide preparation methodsBiological testingEchinocandinSide chain
Provided are a novel echinocandin drug impurity compound, a preparation method therefor, and the use thereof. Compared with the structure of drug micafungin, the echinocandin drug impurity compound has one more hydrophobic acyl side chain. The method comprises first dissolving a side chain active ester in a solvent, adding a basic catalyst, and then adding an appropriate amount of a FR179642 compound for reaction. The provided high-purity echinocandin drug impurity can be applied to quality control of the echinocandin drug as a reference standard for establishing analysis methods.
Owner:SHANGHAI TECHWELL BIOPHARMACEUTICALS CO LTD
An antifungal pharmaceutical composition based on (1,3)-beta-D-glucan synthase inhibitors
The present application relates to the technical field of biological medicine, in particular to an antifungal drug composition based on (1,3)-beta-D-glucan synthase inhibitor and application thereof. In vivo and in vitro experiments prove that the combination of endogenous antibacterial peptide LL-37 and (1,3)-beta-D-glucan synthase inhibitor (such as caspofungin, micafungin, anidulafungin, rezafungin and albaconazole) shows significant synergistic inhibitory effect on multiple drug-resistant pathogenic fungi such as Candida albicans and Candida auris. Since free antibacterial peptides are easily degraded by proteases, the present application is based on the synergistic killing mechanism of breaking the network barrier of fungal cell wall and assisting endogenous defense peptide to target cell membrane, and ingeniously uses the "antibacterial peptide LL-37 expression promoter" to actively up-regulate the synthesis of host natural peptides, which provides a new drug regimen for clinical treatment of deep fungal infection.
